

Chronic Disease Management

People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services

British Columbia, 2000/2001 to 2002/2003

Fiscal Year	Number of people with CHF	Tests					
		ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001	65,673	46%	7%	11%	28%	52%	10%
2001/2002	68,135	46%	9%	13%	26%	52%	11%
2002/2003	70,264	45%	10%	16%	24%	52%	12%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates.

The medicines include:

- Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
- Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
- Beta blockers (therapeutic classes 24080010, 24080002);
- Digoxin (therapeutic class 24040004);
- Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
- Spironolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.



Chronic Disease Management

People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services by HA

British Columbia, 2000/2001 to 2002/2003

Fiscal Year	Health Authority	Number of people with CHF	Tests					
			ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001	Interior	13,885	48.4%	7.6%	10.7%	28.6%	54.2%	11.9%
	Fraser	20,117	45.9%	7.6%	11.3%	27.4%	51.3%	9.0%
	Vancouver Coastal	14,766	42.0%	6.7%	11.2%	25.9%	49.4%	9.0%
	Vancouver Island	12,056	48.3%	7.5%	11.2%	31.2%	54.7%	12.0%
	Northern	3,602	48.9%	6.1%	11.5%	26.3%	53.6%	8.8%
	British Columbia	65,673	46.1%	7.2%	11.1%	27.9%	52.2%	10.2%
2001/2002	Interior	14,684	47.8%	9.1%	13.7%	26.4%	53.8%	13.8%
	Fraser	20,786	46.1%	8.9%	13.3%	25.8%	51.0%	10.3%
	Vancouver Coastal	15,330	42.3%	8.4%	12.9%	24.3%	48.8%	10.2%
	Vancouver Island	12,430	48.2%	9.2%	13.2%	29.3%	54.9%	12.7%
	Northern	3,790	50.1%	7.1%	14.7%	24.6%	53.1%	9.7%
	British Columbia	68,135	46.2%	8.7%	13.3%	26.1%	51.9%	11.4%
2002/2003	Interior	15,363	46.4%	10.3%	15.8%	24.2%	53.5%	14.5%
	Fraser	21,391	45.5%	10.5%	15.4%	24.6%	50.8%	11.4%
	Vancouver Coastal	15,749	41.8%	9.9%	15.2%	22.5%	48.1%	11.0%
	Vancouver Island	12,768	47.3%	10.8%	15.2%	27.3%	54.9%	14.3%
	Northern	4,029	49.1%	8.8%	18.6%	22.4%	53.0%	9.9%
	British Columbia	70,264	45.3%	10.2%	15.5%	24.4%	51.6%	12.4%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates. The medicines include:
 - Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
 - Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
 - Beta blockers (therapeutic classes 24080010, 24080002);
 - Digoxin (therapeutic class 24040004);
 - Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
 - Spirinolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.
- Patients with unknown LHA are not shown separately, but are included in the British Columbia total.



Chronic Disease Management

People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services

Interior Health Authority, 2000/2001 to 2002/2003

Health Service Delivery Area	Number of people with CHF	Tests					
		ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001							
11 - East Kootenay	1,345	47%	5%	15%	27%	57%	9%
12 - Kootenay/Boundary	1,892	49%	7%	10%	30%	55%	10%
13 - Okanagan	6,497	49%	8%	12%	28%	55%	14%
14 - Thompson/Cariboo	4,151	47%	8%	8%	30%	52%	10%
Total	13,885	48%	8%	11%	29%	54%	12%
2001/2002							
11 - East Kootenay	1,403	49%	7%	18%	26%	55%	10%
12 - Kootenay/Boundary	1,967	49%	9%	13%	28%	54%	12%
13 - Okanagan	6,950	49%	10%	16%	25%	55%	16%
14 - Thompson/Cariboo	4,364	46%	9%	10%	28%	51%	12%
Total	14,684	48%	9%	14%	26%	54%	14%
2002/2003							
11 - East Kootenay	1,458	48%	8%	18%	24%	55%	10%
12 - Kootenay/Boundary	1,971	46%	10%	15%	27%	55%	13%
13 - Okanagan	7,307	47%	11%	19%	23%	55%	17%
14 - Thompson/Cariboo	4,627	45%	9%	10%	26%	50%	12%
Total	15,363	46%	10%	16%	24%	54%	15%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates. The medicines include:
 - Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
 - Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
 - Beta blockers (therapeutic classes 24080010, 24080002);
 - Digoxin (therapeutic class 24040004);
 - Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
 - Spirinolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.



Chronic Disease Management

People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services

Fraser Health Authority, 2000/2001 to 2002/2003

Health Service Delivery Area	Number of people with CHF	Tests					
		ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001							
21 - Fraser East	4,816	49%	8%	13%	27%	49%	9%
22 - Fraser North	6,869	44%	7%	10%	28%	52%	9%
23 - Fraser South	8,432	46%	7%	12%	27%	52%	9%
Total	20,117	46%	8%	11%	27%	51%	9%
2001/2002							
21 - Fraser East	4,886	48%	10%	14%	26%	50%	10%
22 - Fraser North	7,077	44%	8%	12%	27%	52%	10%
23 - Fraser South	8,823	46%	9%	14%	24%	51%	11%
Total	20,786	46%	9%	13%	26%	51%	10%
2002/2003							
21 - Fraser East	4,897	48%	11%	16%	25%	51%	11%
22 - Fraser North	7,332	44%	10%	14%	26%	52%	11%
23 - Fraser South	9,162	45%	10%	16%	23%	50%	12%
Total	21,391	45%	10%	15%	25%	51%	11%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates. The medicines include:
 - Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
 - Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
 - Beta blockers (therapeutic classes 24080010, 24080002);
 - Digoxin (therapeutic class 24040004);
 - Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
 - Spirinolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.



Chronic Disease Management

People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services

Vancouver Coastal Health Authority, 2000/2001 to 2002/2003

Health Service Delivery Area	Number of people with CHF	Tests					
		ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001							
31 - Richmond	2,051	40%	9%	15%	24%	50%	12%
32 - Vancouver	8,634	42%	7%	12%	26%	48%	8%
33 - N. Shore/Coast Garibaldi	4,081	43%	5%	8%	26%	51%	11%
Total	14,766	42%	7%	11%	26%	49%	9%
2001/2002							
31 - Richmond	2,185	39%	12%	16%	23%	49%	12%
32 - Vancouver	8,929	42%	8%	13%	24%	47%	9%
33 - N. Shore/Coast Garibaldi	4,216	46%	7%	10%	25%	51%	12%
Total	15,330	42%	8%	13%	24%	49%	10%
2002/2003							
31 - Richmond	2,208	37%	14%	18%	22%	48%	13%
32 - Vancouver	9,197	41%	9%	16%	22%	47%	10%
33 - N. Shore/Coast Garibaldi	4,344	46%	9%	13%	23%	51%	13%
Total	15,749	42%	10%	15%	22%	48%	11%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates. The medicines include:
 - Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
 - Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
 - Beta blockers (therapeutic classes 24080010, 24080002);
 - Digoxin (therapeutic class 24040004);
 - Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
 - Spirinolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.



People with Congestive Heart Failure (CHF) and Proportion Receiving Recommended Services

Vancouver Island Health Authority, 2000/2001 to 2002/2003

Health Service Delivery Area	Number of people with CHF	Tests					
		ACE	ARBs	Beta Blockers	Digoxin	Diuretics	Spirinolactone
2000/2001							
41 - South Vancouver Island	5,644	49%	7%	10%	32%	56%	11%
42 - Central Vancouver Island	4,537	47%	8%	11%	32%	54%	12%
43 - North Vancouver Island	1,875	50%	8%	13%	25%	51%	14%
Total	12,056	48%	7%	11%	31%	55%	12%
2001/2002							
41 - South Vancouver Island	5,754	48%	9%	12%	31%	57%	12%
42 - Central Vancouver Island	4,736	48%	10%	13%	30%	54%	13%
43 - North Vancouver Island	1,940	48%	10%	16%	23%	51%	13%
Total	12,430	48%	9%	13%	29%	55%	13%
2002/2003							
41 - South Vancouver Island	5,841	47%	10%	14%	29%	57%	14%
42 - Central Vancouver Island	4,906	47%	12%	16%	27%	54%	15%
43 - North Vancouver Island	2,021	47%	12%	18%	22%	53%	13%
Total	12,768	47%	11%	15%	27%	55%	14%

Notes:

- Beneficiaries insured under the Medical Services Plan (MSP) were assumed to have congestive heart failure (CHF) if they met the following case definition since 1992/1993: one or more acute inpatient hospital admissions where CHF was given as a diagnosis; or two or more physician services within a year where CHF was given as a diagnosis. The claims data includes services provided to BC patients by BC practitioners with medical specialties 00 to 21, 23, 24, 28, 29, 33, 44, 47 and 48. Medical services paid by MSP and Primary Care are included; services paid by the Alternative Payments Program, ICBC, WCB or other arrangements such as reciprocals and midwife referrals, are excluded.
- The Health Service Delivery Area refers to the location of the patient, based on the patient's reported postal code with the highest MSP paid services count during the fiscal year. For patients without MSP paid services, the Local Health Area is the postal code reported in the Client Registry.
- Patients are flagged for a measure of the recommended services if during the fiscal year they receive two or more scripts for a medicine on different dates. The medicines include:
 - Angiotensin converting enzyme inhibitors (ACE inhibitors) (therapeutic classes 24080036, 24080028, 24040002, 24080029, 24080031, 24080034, 24080032);
 - Angiotensin II receptor antagonists or blockers (ARBs) (therapeutic classes 24080042, 24080040, 24080041, 24080037, 24080043);
 - Beta blockers (therapeutic classes 24080010, 24080002);
 - Digoxin (therapeutic class 24040004);
 - Diuretics other than spironolactone (therapeutic classes 40280014, 40280009, 40280006, 40280013, 40281003, 40281001, 40280019); and
 - Spirinolactone (therapeutic class 40281002).

These pharmaceutical services are tracked using PharmaNet.

